Loading...
•
Sep 30, 2024
Twist Bioscience Q4 2024 Earnings Report
Twist Bioscience reported record revenue and gross margin improved.
Key Takeaways
Twist Bioscience reported record revenue of $84.7 million for Q4 2024, a 27% increase compared to the same period last year. The gross margin improved to 45.1%. The company exceeded its guidance for the quarter and year, ending the fiscal year with $313.0 million in revenue and a strong cash position.
Total revenues for the fourth quarter of fiscal 2024 grew 27% to $84.7 million compared to $66.9 million for the same period of fiscal 2023.
Gross margin for the fourth quarter of fiscal 2024 increased to 45.1% compared to 36.6% for the same period of fiscal 2023.
Net loss attributable to common stockholders for the fourth quarter of fiscal 2024 decreased to $34.7 million, or $0.59 per share, compared to $46.2 million, or $0.81 per share, for the same period of fiscal 2023.
Total orders received for the fourth quarter of fiscal 2024 grew 24% to $88.2 million compared to $71.1 million for the same period of fiscal 2023.
Twist Bioscience
Twist Bioscience
Twist Bioscience Revenue by Segment
Revenue by Segment
SynBio Revenue
CapyFin.comNGS Revenue
CapyFin.comBiopharma Revenue
CapyFin.com Forward Guidance
Twist Bioscience expects total revenue to be in the range of $367 million to $377 million for the full fiscal year 2025, with a gross margin of approximately 48% for fiscal 2025 and 4QFY25 gross margin of 50%.
Positive Outlook
- Total revenue is expected to be in the range of $367 million to $377 million, growth of 17 to 20 percent year over year
- SynBio revenue of $142 to $146 million, growth of 15 to 18 percent
- NGS revenue of $204 to $209 million, growth of 20 to 24 percent
- Biopharma revenue of $21 to $22 million, growth of 5 to 8 percent
- Gross margin is projected to be approximately 48% for fiscal 2025 with quarterly sequential improvements and 4QFY25 gross margin of 50%
Challenges Ahead
- Adjusted EBITDA of approximately $(60) to $(65) million for fiscal 2025
- Total revenue of approximately $87 million for the first quarter
- SynBio revenue of approximately $34 million, growth of 26% year over year for the first quarter
- NGS revenue of approximately $48 million, growth of 22% year over year for the first quarter
- Adjusted EBITDA of approximately $(20) million with sequential improvements throughout 2025 for the first quarter
Revenue & Expenses
Visualization of income flow from segment revenue to net income